NASDAQ:GBT - Global Blood Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $66.20
Forecasted Upside: 128.35 %
Number of Analysts: 12
Breakdown:
0 Sell Ratings
2 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$28.99 As of 01/14/2022 01:00 AM ET

▲ +1.26 (4.54%)

1 month | 3 months | 12 months

Get New Global Blood Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for GBT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GBT

^$66.20

▲ +128.35% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Global Blood Therapeutics in the last 3 months. The average price target is $66.20, with a high forecast of $124.00 and a low forecast of $36.00. The average price target represents a 128.35% upside from the last price of $28.99.

Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Global Blood Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
15 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/26/2020

0 strong buy ratings
15 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/24/2020

0 strong buy ratings
13 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/22/2021

0 strong buy ratings
15 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/22/2021

0 strong buy ratings
10 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

7/21/2021

0 strong buy ratings
13 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

10/19/2021

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

12/18/2021

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/17/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
12/21/2021	SVB Leerink	Lower Price Target	Outperform	$56.00 ➝ $53.00	Low
12/14/2021	SVB Leerink	Boost Price Target	Outperform	$54.00 ➝ $56.00	High
12/7/2021	William Blair	Upgrade	Market Perform ➝ Outperform		High
11/5/2021	Royal Bank of Canada	Lower Price Target	Outperform	$66.00 ➝ $64.00	High
10/6/2021	Jefferies Financial Group	Initiated Coverage	Buy	$68.00	High
9/8/2021	Wedbush	Reiterated Rating	Buy		Low
8/4/2021	Truist Securities	Upgrade	Buy	$45.00 ➝ $50.00	High
8/4/2021	Piper Sandler	Lower Price Target	Neutral	$45.00 ➝ $40.00	High
8/4/2021	Truist	Upgrade	Hold ➝ Buy	$45.00 ➝ $50.00	High
6/28/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$70.00 ➝ $36.00	High
5/7/2021	Cantor Fitzgerald	Lower Price Target	Overweight	$120.00 ➝ $110.00	Low
5/6/2021	Piper Sandler	Lower Price Target		$50.00 ➝ $45.00	High
5/6/2021	Roth Capital	Lower Price Target	Buy	$128.00 ➝ $124.00	High
4/14/2021	SVB Leerink	Initiated Coverage	Outperform	$54.00	Low
3/11/2021	Wolfe Research	Initiated Coverage	Outperform	$67.00	Low
2/25/2021	William Blair	Downgrade	Outperform ➝ Market Perform		High
1/20/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$75.00 ➝ $50.00	Low
12/16/2020	Morgan Stanley	Lower Price Target	Equal Weight	$67.00 ➝ $45.00	Low
12/15/2020	HC Wainwright	Reiterated Rating	Buy	$75.00	Low
12/8/2020	William Blair	Reiterated Rating	Buy		Medium
12/3/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$75.00	High
11/18/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$133.00 ➝ $120.00	Low
11/9/2020	Truist	Lower Price Target		$78.00 ➝ $55.00	Low
11/6/2020	Morgan Stanley	Lower Price Target	Equal Weight	$68.00 ➝ $67.00	High
11/6/2020	Roth Capital	Lower Price Target	Buy	$131.00 ➝ $128.00	High
11/6/2020	Stifel Nicolaus	Lower Price Target	Buy	$120.00 ➝ $101.00	High
11/6/2020	Piper Sandler	Boost Price Target	Overweight	$75.00 ➝ $120.00	High
11/6/2020	Oppenheimer	Lower Price Target	Outperform	$102.00 ➝ $92.00	High
11/6/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		High
10/13/2020	Morgan Stanley	Lower Price Target	Equal Weight	$75.00 ➝ $68.00	High
10/6/2020	Evercore ISI	Initiated Coverage	Outperform	$102.00	Medium
8/25/2020	Wedbush	Boost Price Target		$145.00 ➝ $152.00	Medium
8/24/2020	Raymond James	Initiated Coverage	Outperform	$115.00	Medium
8/6/2020	HC Wainwright	Reiterated Rating	Buy	$150.00	Low
8/6/2020	Stifel Nicolaus	Boost Price Target	Buy	$113.00 ➝ $118.00	High
7/29/2020	Piper Sandler	Reiterated Rating	Buy	$120.00	Low
7/20/2020	Roth Capital	Initiated Coverage	Buy	$129.00	Low
7/13/2020	Bank of America	Initiated Coverage	Buy	$92.00	High
7/1/2020	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$91.00 ➝ $103.00	High
6/25/2020	HC Wainwright	Reiterated Rating	Buy	$150.00	Low
6/23/2020	Wedbush	Reiterated Rating	Buy	$145.00	High
6/15/2020	Oppenheimer	Reiterated Rating	Buy	$101.00	High
6/12/2020	Wells Fargo & Company	Reiterated Rating	Buy		High
5/12/2020	Wedbush	Reiterated Rating	Buy	$145.00	Low
5/7/2020	Cantor Fitzgerald	Boost Price Target		$105.00 ➝ $130.00	Low
5/7/2020	Nomura	Reiterated Rating	Buy	$112.00	Low
5/7/2020	Wells Fargo & Company	Boost Price Target	Overweight	$122.00 ➝ $133.00	Medium
5/7/2020	Oppenheimer	Boost Price Target	Outperform	$88.00 ➝ $101.00	Low
5/7/2020	Morgan Stanley	Boost Price Target	Equal Weight	$70.00 ➝ $75.00	High
4/27/2020	Stifel Nicolaus	Initiated Coverage	Buy	$112.00	Low
4/15/2020	Morgan Stanley	Lower Price Target	Equal Weight	$71.00 ➝ $70.00	Low
3/19/2020	Wedbush	Reiterated Rating	Buy	$145.00	Medium
3/18/2020	Oppenheimer	Lower Price Target		$100.00 ➝ $88.00	Low
3/3/2020	Morgan Stanley	Lower Price Target	Equal Weight	$80.00 ➝ $71.00	High
1/31/2020	SunTrust Banks	Downgrade	Buy ➝ Hold	$110.00 ➝ $75.00	High
1/17/2020	Morgan Stanley	Boost Price Target	Equal Weight	$79.00 ➝ $80.00	Medium
12/23/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$120.00	N/A
12/22/2019	Wedbush	Reiterated Rating	Buy	$143.00	Medium
12/18/2019	William Blair	Reiterated Rating	Buy		High
12/17/2019	JPMorgan Chase & Co.	Boost Price Target	Equal Weight	$58.00 ➝ $79.00	Low
12/10/2019	Piper Jaffray Companies	Boost Price Target		$95.00 ➝ $120.00	High
12/9/2019	Oppenheimer	Reiterated Rating	Buy	$100.00	Low
11/26/2019	Nomura Securities	Boost Price Target	Buy	$109.00 ➝ $112.00	High
11/26/2019	Wedbush	Reiterated Rating	Buy	$143.00	High
11/26/2019	Janney Montgomery Scott	Boost Price Target	Buy	$75.00 ➝ $90.00	High
11/26/2019	SunTrust Banks	Boost Price Target	Buy	$110.00	High
11/26/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$80.00 ➝ $95.00	High
11/25/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$110.00 ➝ $98.00	High
10/17/2019	Cantor Fitzgerald	Reiterated Rating	Overweight		High
10/14/2019	SunTrust Banks	Boost Price Target	Buy	$100.00	Low
10/9/2019	Cowen	Set Price Target	Buy	$83.00	Low
10/9/2019	Wedbush	Reiterated Rating	Buy	$120.00	Low
10/9/2019	Wells Fargo & Company	Boost Price Target	Outperform	$96.00 ➝ $104.00	Medium
10/9/2019	HC Wainwright	Reiterated Rating	Buy	$150.00	Medium
10/8/2019	William Blair	Reiterated Rating	Buy		Low
9/12/2019	Wedbush	Reiterated Rating	Buy	$120.00	Medium
9/6/2019	HC Wainwright	Set Price Target	Buy	$150.00	Low
9/5/2019	Cowen	Set Price Target	Buy	$83.00	Low
9/5/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
9/5/2019	Wedbush	Boost Price Target	Outperform ➝ Hold	$103.00 ➝ $120.00	High
8/12/2019	Wedbush	Reiterated Rating	Outperform	$103.00	Low
8/11/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	Low
8/9/2019	Morgan Stanley	Set Price Target	Hold	$60.00	Medium
8/8/2019	Cowen	Reiterated Rating	Buy	$83.00	Low
8/8/2019	HC Wainwright	Reiterated Rating	Buy	$150.00	Low
6/28/2019	Wedbush	Set Price Target	Buy	$103.00	Medium
6/25/2019	HC Wainwright	Reiterated Rating	Buy		Low
6/17/2019	Wedbush	Reiterated Rating	Buy	$107.00	Medium
6/16/2019	Cowen	Reiterated Rating	Buy		Medium
6/14/2019	Cantor Fitzgerald	Set Price Target	Buy	$96.00 ➝ $110.00	High
6/11/2019	Wedbush	Reiterated Rating	Buy	$107.00	Low
6/3/2019	Wedbush	Reiterated Rating	Buy	$95.00 ➝ $107.00	High
5/29/2019	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$75.00	Low
5/13/2019	Wedbush	Reiterated Rating	Buy	$95.00	High
5/9/2019	Oppenheimer	Boost Price Target	Outperform	$82.00 ➝ $89.00	Medium
4/18/2019	Wedbush	Reiterated Rating	Outperform	$95.00	Medium
4/12/2019	HC Wainwright	Set Price Target	Buy	$150.00	High
4/1/2019	Wells Fargo & Company	Boost Price Target	Outperform ➝ Outperform	$85.00 ➝ $96.00	Low
3/5/2019	Wedbush	Boost Price Target	Outperform ➝ Outperform	$91.00 ➝ $95.00	Low
3/4/2019	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$55.00 ➝ $57.00	Low
2/28/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	Low
2/22/2019	Guggenheim	Initiated Coverage	Buy	$75.00	Low
1/30/2019	William Blair	Reiterated Rating	Buy		High
12/19/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$54.00 ➝ $55.00	High
12/4/2018	SunTrust Banks	Boost Price Target	Buy ➝ Positive	$90.00	Medium
12/4/2018	HC Wainwright	Set Price Target	Buy	$150.00	Medium
12/3/2018	William Blair	Reiterated Rating	Buy		High
12/3/2018	Cantor Fitzgerald	Set Price Target	Buy	$96.00	High
12/3/2018	Oppenheimer	Set Price Target	Buy	$82.00	High
11/28/2018	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$150.00	High
11/19/2018	Wedbush	Reiterated Rating	Buy	$73.00	Low
11/7/2018	Oppenheimer	Set Price Target	Buy	$74.00 ➝ $82.00	High
11/7/2018	William Blair	Reiterated Rating	Buy		High
11/5/2018	HC Wainwright	Set Price Target	Buy	$125.00	Low
11/1/2018	Oppenheimer	Set Price Target	Buy	$74.00	Medium
10/23/2018	Cantor Fitzgerald	Set Price Target	Buy	$96.00	Low
10/19/2018	HC Wainwright	Set Price Target	Buy	$125.00	High
10/18/2018	William Blair	Reiterated Rating	Buy		High
10/17/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$96.00	High
10/2/2018	Cantor Fitzgerald	Set Price Target	Buy	$96.00	High
9/13/2018	HC Wainwright	Set Price Target	Buy	$125.00	High
8/23/2018	Cantor Fitzgerald	Set Price Target	Buy	$96.00	Medium
8/23/2018	HC Wainwright	Set Price Target	Buy	$125.00	Low
8/13/2018	Cowen	Reiterated Rating	Buy	$83.00	High
8/8/2018	HC Wainwright	Set Price Target	Buy	$125.00	Low
8/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$96.00	Low
8/6/2018	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$73.00	Low
8/6/2018	Piper Jaffray Companies	Initiated Coverage	Overweight	$80.00	Low
8/5/2018	SunTrust Banks	Set Price Target	Buy	$70.00	Low
8/5/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	Low
8/2/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$96.00	High
7/27/2018	HC Wainwright	Reiterated Rating	Buy	$125.00	High
6/28/2018	Nomura Securities	Boost Price Target	Buy ➝ Buy	$91.00 ➝ $109.00	High
6/27/2018	HC Wainwright	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $125.00	High
6/27/2018	Wells Fargo & Company	Boost Price Target	Outperform	$78.00 ➝ $85.00	High
6/27/2018	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$69.00 ➝ $96.00	High
6/18/2018	Wedbush	Reiterated Rating	Outperform	$70.00	Low
5/24/2018	HC Wainwright	Set Price Target	Buy	$73.00	Low
5/21/2018	Wedbush	Reiterated Rating	Outperform	$70.00	High
5/10/2018	HC Wainwright	Set Price Target	Buy	$73.00	Medium
5/9/2018	Cantor Fitzgerald	Set Price Target	Buy	$69.00	Medium
5/8/2018	SunTrust Banks	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $77.00	High
5/8/2018	Oppenheimer	Lower Price Target	Outperform ➝ Outperform	$79.00 ➝ $74.00	High
4/26/2018	Needham & Company LLC	Reiterated Rating	Buy	$70.00	High
3/21/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$61.00	High
3/14/2018	Wedbush	Reiterated Rating	Outperform	$73.00	Low
3/12/2018	HC Wainwright	Set Price Target	Buy	$73.00	High
3/6/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$58.00 ➝ $61.00	Low
3/1/2018	SunTrust Banks	Set Price Target	Positive ➝ Buy	$80.00	Medium
2/28/2018	William Blair	Reiterated Rating	Buy		High
2/28/2018	HC Wainwright	Set Price Target	Buy	$73.00	High
2/27/2018	Cantor Fitzgerald	Set Price Target	Overweight ➝ Overweight	$61.00 ➝ $72.00	High
2/13/2018	Janney Montgomery Scott	Initiated Coverage	Buy ➝ Buy	$75.00	Medium
1/23/2018	William Blair	Initiated Coverage	Outperform ➝ Outperform	$80.00	High
1/11/2018	HC Wainwright	Set Price Target	Buy	$73.00	Medium
12/15/2017	Wedbush	Reiterated Rating	Outperform	$73.00	Low
12/14/2017	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$51.00 ➝ $70.00	Low
12/12/2017	Oppenheimer	Set Price Target	Buy	$53.00 ➝ $79.00	High
12/11/2017	Nomura Securities	Boost Price Target	Buy	$91.00	High
12/11/2017	HC Wainwright	Set Price Target	Buy	$73.00	High
12/11/2017	Cantor Fitzgerald	Set Price Target	Buy	$61.00	High
12/4/2017	Wedbush	Reiterated Rating	Outperform	$73.00	High
12/1/2017	HC Wainwright	Initiated Coverage	Buy	$73.00	High
11/13/2017	Oppenheimer	Set Price Target	Buy	$53.00	N/A
11/9/2017	Cowen	Reiterated Rating	Buy	$83.00	N/A
11/6/2017	SunTrust Banks	Boost Price Target	Buy	$67.00	N/A
10/30/2017	Oppenheimer	Set Price Target	Buy	$53.00	N/A
10/24/2017	Needham & Company LLC	Set Price Target	Buy	$51.00	N/A
10/23/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A
10/23/2017	Oppenheimer	Set Price Target	Buy	$53.00	N/A
10/18/2017	Needham & Company LLC	Set Price Target	Buy	$51.00	N/A
10/11/2017	Oppenheimer	Set Price Target	Buy	$53.00	N/A
10/6/2017	Morgan Stanley	Reiterated Rating	Overweight	$51.00 ➝ $56.00	N/A
9/20/2017	Needham & Company LLC	Initiated Coverage	Buy ➝ Buy	$51.00	High
9/18/2017	Wedbush	Reiterated Rating	Ourperform	$73.00	Medium
8/14/2017	Cowen	Reiterated Rating	Outperform	$83.00	Medium
8/8/2017	JPMorgan Chase & Co.	Reiterated Rating	Overweight ➝ Overweight	$44.00 ➝ $46.00	Medium
8/4/2017	Oppenheimer	Initiated Coverage	Outperform	$53.00	High
7/11/2017	Morgan Stanley	Reiterated Rating	Overweight		Low
5/2/2017	Wedbush	Reiterated Rating	Outperform	$73.00	High
5/1/2017	Janney Montgomery Scott	Initiated Coverage	Buy	$37.00	Low
4/17/2017	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$56.00	High
3/20/2017	Roth Capital	Set Price Target	Buy	$47.00	Low
3/20/2017	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$73.00	Low
3/15/2017	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$61.00	Low
3/15/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy	$44.00	Medium
3/1/2017	Nomura Instinet	Initiated Coverage	Buy ➝ Buy	$50.00	N/A
3/1/2017	Nomura Securities	Initiated Coverage	Buy		N/A
2/18/2017	Roth Capital	Set Price Target	Buy	$47.00	N/A

(Data available from 1/17/2017 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/21/2021

0 very positive mentions
3 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

7/21/2021

2 very positive mentions
6 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

8/20/2021

8 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/19/2021

1 very positive mentions
5 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

10/19/2021

2 very positive mentions
7 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

11/18/2021

8 very positive mentions
4 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

12/18/2021

5 very positive mentions
5 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

1/17/2022

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

Today's Range

Now: $28.99

$27.14

$29.13

50 Day Range

MA: $29.96

$24.90

$33.87

52 Week Range

Now: $28.99

$24.61

$52.49

Volume

1,122,121 shs

Average Volume

1,190,240 shs

Market Capitalization

$1.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Global Blood Therapeutics?: The following sell-side analysts have issued reports on Global Blood Therapeutics in the last twelve months: Cantor Fitzgerald, Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, Roth Capital, Royal Bank of Canada, SVB Leerink LLC, Truist, Truist Securities, Wedbush, William Blair, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for GBT.
What is the current price target for Global Blood Therapeutics?: 10 Wall Street analysts have set twelve-month price targets for Global Blood Therapeutics in the last year. Their average twelve-month price target is $66.20, suggesting a possible upside of 128.4%. Roth Capital has the highest price target set, predicting GBT will reach $124.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $36.00 for Global Blood Therapeutics in the next year.
View the latest price targets for GBT.
What is the current consensus analyst rating for Global Blood Therapeutics?: Global Blood Therapeutics currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GBT will outperform the market and that investors should add to their positions of Global Blood Therapeutics.
View the latest ratings for GBT.
What other companies compete with Global Blood Therapeutics?: Other companies that are similar to Global Blood Therapeutics include Ascendis Pharma A/S, Mirati Therapeutics, Legend Biotech, Sarepta Therapeutics, Arrowhead Pharmaceuticals, Arena Pharmaceuticals, HUTCHMED, Perrigo, Ultragenyx Pharmaceutical, Zai Lab, Ionis Pharmaceuticals, Blueprint Medicines, CureVac, Alkermes and Cerevel Therapeutics.
How do I contact Global Blood Therapeutics' investor relations team?: Global Blood Therapeutics' physical mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 741-7700 and its investor relations email address is [email protected] The official website for Global Blood Therapeutics is www.gbt.com.

NASDAQ:GBT - Global Blood Therapeutics Stock Price Target and Predictions

Analyst Price Target for GBT

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.65 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Global Blood Therapeutics?

What is the current price target for Global Blood Therapeutics?

What is the current consensus analyst rating for Global Blood Therapeutics?

What other companies compete with Global Blood Therapeutics?

How do I contact Global Blood Therapeutics' investor relations team?